Kisqali (Ribociclib)
Kisqali (Ribociclib)
Kisqali (Ribociclib) is used in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. As a CDK4/6 inhibitor, Kisqali effectively slows down the growth of cancer cells by interfering with their division and proliferation.
Why Choose Kisqali (Ribociclib)?
- Effective Combination Therapy: Works effectively in conjunction with an aromatase inhibitor or fulvestrant in premenopausal, perimenopausal, and postmenopausal women.
- Progression-Free Survival: This has been shown to significantly increase progression-free survival compared to endocrine therapy alone.
- Oral Administration: Convenient oral tablet form, facilitating ease of use in outpatient settings.
- Flexible Dosing: Available in multiple dosages, allowing for flexible treatment regimens tailored to patient needs.
How to Use Kisqali (Ribociclib)?
- Dosage and Administration: Kisqali is taken orally, once daily for 21 consecutive days followed by 7 days off to complete a 28-day cycle. It should be taken with or without food at approximately the same time each day.
- Combination Therapy: Must be used in combination with an aromatase inhibitor or fulvestrant as directed by a healthcare provider.
- Monitoring: Regular monitoring of blood counts and liver function tests is required to adjust doses to manage side effects effectively.
Important Safety Information about Kisqali
- Not for Everyone: Kisqali is not suitable for patients with known severe hypersensitivity to ribociclib or any of its components.
- Blood Cell Counts: Patients must have their complete blood count monitored before starting treatment and regularly throughout treatment as Kisqali can result in low white blood cell counts.
- Heart Health: Patients should have heart function tests before and during treatment since Kisqali can cause heart problems.
Fact Table
| Facts | Details |
| Generic Name | Ribociclib |
| Brand Name | Kisqali |
| Drug Class | CDK4/6 inhibitor |
| FDA Approval | Initially approved in March 2017 |
| Indication | Used for the treatment of HR+/HER2- advanced or metastatic breast cancer |
| Administration | Oral tablets |
| Dosage Form | Tablets available in 200 mg, 400 mg, and 600 mg |
| Treatment Regimen | 21 days on, 7 days off to complete a 28-day cycle |
| Combination Therapy | Often used with an aromatase inhibitor or fulvestrant |
| Primary Side Effects | Neutropenia, leukopenia, fatigue, nausea, vomiting, headache, hair loss |
| Monitoring Requirements | Blood counts, liver function, heart function tests |
| Special Considerations | Not suitable for patients with severe hypersensitivity to ribociclib or its components. Requires periodic monitoring of liver function and blood cell counts. |
| Mechanism of Action | Inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), which are involved in the proliferation of cancer cells |
Common Side Effects
Like all medications, Kisqali (Ribociclib) can cause side effects, although not everybody gets them. Understanding these side effects can help you use this medication safely and effectively.
- Fatigue
- Nausea and Vomiting
- Headache
- Hair Loss
If you experience any side effects, discuss them with your healthcare provider. They can offer advice and may adjust your treatment if necessary. Report any severe or unexpected side effects immediately.
How Can You Buy Kisqali (Ribociclib)?
You can order Kisqali (Ribociclib) using these methods on our website:
- Order Online
- Order by Phone
- Order by Fax
- Order your refills
Visit our How to order page.
